Manufacturer: Dragon Pharma
Pharmaceutical name: Survodutide
Pack: 1 vial (10 mg)
Survodutide (BI-456906) is currently in development for addressing renal failure, non-alcoholic steatohepatitis (NASH), liver fibrosis, type 2 diabetes, and obesity. It is administered weekly via subcutaneous and parenteral routes. Its mechanism involves targeting the glucagon-like peptide 1 receptor (GLP1R).
Survodutide is gaining considerable interest for its potential in treating various metabolic disorders. This innovative medication primarily focuses on metabolic pathways, particularly those related to obesity and type 2 diabetes. Research organizations worldwide are dedicated to exploring and advancing Survodutide, with several prominent pharmaceutical companies leading its development.
Survodutide is categorized as a dual agonist, meaning it interacts with two distinct receptor types in the body. These receptors are crucial in regulating metabolic functions, especially those associated with glucose management and fat metabolism. The drug currently targets obesity and type 2 diabetes, two ailments that have become widespread globally. Various clinical trials are underway, with early-stage studies demonstrating encouraging results regarding efficacy and safety.
The mode of action of Survodutide is intricate and intriguing. As a dual agonist, it activates both the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. These receptors are essential in regulating appetite, insulin release, and glucose processing. By engaging both receptors, Survodutide offers a more holistic strategy for managing metabolic disorders compared to medications that act on only one receptor.
GLP-1 is a hormone that boosts insulin secretion in reaction to meals while inhibiting glucagon release, a hormone that elevates blood glucose levels. Moreover, GLP-1 slows gastric emptying, which extends the feeling of fullness and decreases overall food intake. Conversely, GIP also influences insulin secretion and plays a role in fat metabolism by facilitating fat storage in adipose tissues. By targeting both receptors, Survodutide aids in blood glucose regulation, weight loss, and improved fat metabolism.
The primary indications for Survodutide are obesity and type 2 diabetes. Obesity involves excess fat accumulation that poses health risks, leading to complications such as cardiovascular disease, certain cancers, and type 2 diabetes. Type 2 diabetes is a chronic condition that disrupts how the body manages blood sugar (glucose), often linked to obesity, and can result in serious complications if not effectively controlled.
For those struggling with obesity, Survodutide presents a promising new option. Conventional weight loss strategies like dieting and exercising frequently yield limited results, leaving many patients unable to achieve and sustain significant weight loss. Survodutide, by addressing two essential metabolic pathways, has shown in clinical trials to substantially decrease body weight in obese individuals. Its dual agonist effect helps curb appetite and enhance fat oxidation, facilitating lasting weight loss.